About Danaher Corp
- Industry: Life Sciences Tools & Services
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.danaher.com/
Frequently Asked Questions
What is the 52-week range for DHR?
The 52-week high is $242.8 and the 52-week low is $160.93.
What is the P/E ratio for DHR?
The Price to Earnings (P/E) ratio is 37.77.
What is the dividend yield for DHR?
The indicated annual dividend yield is 0.49%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 7.66%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 15.95%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.08.
Analyst Recommendation Trends
Wall Street analyst consensus for DHR over the last few months:
Latest DHR News
CPM Names Jeremy Patten Chief Executive Officer
CPM logo CPM is a leading global provider of process equipment, engineered technologies and aftermarket parts and services serving customers across the food, fuel and industrial markets. With a global installed base and portfolio of industry-leading brands, CPM supports customers from new equipment and process solutions through parts, service, upgrades and ongoing equipment support. For more information, visit onecpm.com. Jeremy Patten Jeremy Patten has joined the CPM as Chief Executive Officer.
Parker-Hannifin Benefits From Business Strength Amid Headwinds
PH's aerospace and industrial growth, acquisitions and portfolio shift support momentum as rising costs and debt weigh on results.
Perimeter Medical Imaging AI Appoints Finance Executive Michelle Caron to Board of Directors
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that Michelle Caron, CPA, has been appointed to its Board of Directors, effective immediately.
Why Danaher (DHR) Shares Are Trading Lower Today
Shares of diversified science and technology company Danaher (NYSE:DHR) fell 3.9% in the afternoon session after the company announced that Julie Sawyer Montgomery assumed the roles of president and chief executive officer and joined the board of directors.
What's going on in today's session: S&P500 movers
Get insights into the S&P500 index performance on Thursday. Explore the top gainers and losers within the S&P500 index in today's session.
What You Need to Know Ahead of Danaher’s Earnings Release
Danaher is heading into its third-quarter earnings report in the coming weeks, and Wall Street expects modest, low-single-digit earnings growth.
Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer
Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that, effective today, Julie Sawyer Montgomery has assumed the roles of President and Chief Executive Officer and has joined Danaher's Board of Directors, as previously announced on August 3, 2026. Since joining the Company in 2017, Ms. Sawyer Montgomery has held roles of increasing responsibility spanning commercial operations, R&D, and business leadership. In those roles, she has built a track record of advancing innovation
Guggenheim Maintains Buy on Danaher, Raises Price Target to $250
Guggenheim analyst Subbu Nambi maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $200 to $250.
The Top HealthTech Questions Landing On Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.
DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?
Danaher's Biotechnology segment posts 4% sales growth, but tough comparisons and shipment timing could test its momentum.
Masimo Wins Two OCTANE High Tech Awards - Company Recognized for 'Deal of the Year' and 'Best Technology Leadership Team'
Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced that it received two honors at the 2026 Octane High Tech Awards, winning Deal of the Year and Best Technology Company Leadership Team.
Oura IPO: What to Know Ahead of This Week’s Public Debut
The maker of rings is expected to price its initial public offering after the market close on Tuesday.
Oura IPO Looks to Cash In on Growing Consumer Interest in Health Data
The maker of rings is expected to price its initial public offering after the market close on Tuesday.
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?
Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that is expanding at a double-digit rate, with newer products contributing more and resulting in management raising its sales outlook. […]
Leica Biosystems Completes Acquisition of StatLab to Bolster Delivery of More Precise, Timely Diagnostics for Cancer Patients
Leica Biosystems, a Danaher company (the "Company") and a global leader in digital and anatomic pathology solutions advancing precision cancer diagnostics, announced today that the Company has completed its acquisition of privately held StatLab Medical Products ("StatLab"), a leading provider of pre-analytical consumables and equipment, from Linden Capital Partners and Audax Private Equity. For patients and their care teams, precision cancer diagnostics can provide critical information about the
Dividend Champion, Contender, And Challenger Highlights: Week September 27
Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.
TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher
Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision medicine, especially in Asia-Pacific.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "TDM Reagent Kit Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global TDM Reagent Kit Market, projected to reach USD 2.87 billion in 2026 and grow at a CAGR of 15.84% to USD 6.96 billion
Danaher Isn't Anything Special, Even After Absorbing Masimo
Danaher (DHR) stays a hold: modest core growth and higher leverage after the Masimo acquisition limit upside despite synergies.
Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth
Danaher has delivered a 17.4% gain over the past year, which puts a spotlight on one core issue for anyone looking at the stock today: whether the current share price can be explained by the cash flows the business is expected to generate. The 17.4% 1 year return means recent buyers have seen a clear payoff, which raises the question of how much future cash generation is already reflected in the valuation. Recent reports on areas such as label free detection and single use bioreactors...
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the
Global Pharmaceutical Filtration Report: Biologics Manufacturing Shifts as Danaher, Merck KGaA, Sartorius, 3M and Thermo Fisher Reshape the Market
Biologics, stricter purity rules and flexible manufacturing are driving demand for single-use, automated and continuous filtration, advanced membranes and sustainable systems.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Filtration - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pharmaceutical Filtration was estimated at US$8.0 Billion in 2025 and is projected to reach US$23.4 Billion by 2032, growing at a CAGR of 16.7% f
Bioreactors Market Outlook 2026-2035 - Featuring Profiles of 3 Leading Companies: Sartorius, Thermo Fisher Scientific, and Danaher
Bioreactors Market Gains Momentum as Single-Use Systems, Automation and Advanced Therapies Reshape BiomanufacturingDublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Bioreactors Market Opportunity, Growth Drivers, Industry Trend Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Bioreactors Market to Reach USD 38.9 Billion by 2035 as Advanced Biomanufacturing Expands The global bioreactors market was valued at USD 13.8 billion in 2025 and is projected to reach
Danaher Schedules Third Quarter 2026 Earnings Conference Call
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.
Stock Market Today: Dow Skids As Trump Threatens Iran; Medical Diagnostics Plays Swoon (Live Coverage)
Stock Market Today: The Dow Jones index was lower after President Trump threatened Iran at the UN. Apple stock is near a buy point.
Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030
AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-Free Detection - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4
Capitalize on the Aseptic Sampling Shift: Benchmark Merck KGaA, Sartorius, Thermo Fisher Scientific, Danaher and GEA to Secure Bioprocessing ROI Across the Forecast Period
Demand is rising for single-use, automated and real-time aseptic sampling as biopharma and food producers prioritize contamination control, continuous manufacturing and compliance.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Aseptic Sampling - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Aseptic Sampling was estimated at US$867.4 Million in 2025 and is projected to reach US$1.3 Billion by 2032, growing at a CAGR of 6.3% from 2025 to 2
Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue
High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Content Screening (HCS) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing
Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better
Healthcare services and products company Cardinal Health (NYSE:CAH)’s shares are up by more than 10% year-to-date but are down by more than 8% since early September. Cramer discussed the firm’s share price performance in his morning appearance on September 15th and wondered whether the weakness was due to a rotation into AI stocks rather than […]
1 Mid-Cap Stock on Our Buy List and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
2 Unpopular Stocks That Should Get More Attention and 1 We Question
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Danaher (DHR) Could Be 8% Below Fair Value Following Its Dividend Reaffirmation
Danaher (DHR) has reaffirmed its shareholder payout, with the Board approving a regular quarterly cash dividend of $0.40 per share, payable on October 30, 2026, to holders of record on September 30. The reaffirmed dividend lands at a time when Danaher’s short-term momentum has picked up. The 90-day share price return is 17.78% and the 1-year total shareholder return is 10.73%, even though the 5-year total shareholder return is down 25.46%. Compare Danaher’s mix of dividend income and recent...
Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players
The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and Nor
Should You Buy Donaldson Stock While Its Share Count Stops Shrinking?
Donaldson (DCI) has gained 9.1% over the past twelve months and still trades about 20% below its 52-week high. The filtration company behind those numbers sells replacement parts into equipment already in service, and the cash from that stream has been steadily shrinking its share count. The shrinking count is the case for buying the pullback. It is also the part that goes quiet in fiscal 2027.
Danaher Announces Quarterly Dividend
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.
ELV or DHR: Which Is the Better Value Stock Right Now?
ELV vs. DHR: Which Stock Is the Better Value Option?
High Content Screening Market Forecasts Growth from $3.37B (2026) to $6.58B by 2032, Profiling Thermo Fisher, Danaher, GE HealthCare & 27 Other Key Players
Opportunities center on AI-enabled imaging, lab automation, advanced 3D and patient-derived cell models, CRO partnerships, and expanding global life sciences research.Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "High Content Screening Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global High Content Screening Market, projected to reach USD 3.37 billion in 2026 and USD 6.58 billion by 2032, representing a CAGR of 1
Single-Use Bioreactors Market by Product, Type, Cell Type, Molecule, Process Mode, Application, Competition, Region - Global Forecast to 2031
The global single-use bioreactors market is forecast to grow from USD 5.43 billion in 2026 to USD 9.58 billion by 2031, at a 12.0% CAGR. Growth is driven by biologics, biosimilars, vaccine manufacturing, CDMO outsourcing, and flexible bioprocessing. Bioproduction and monoclonal antibodies led the market in 2025, while Asia Pacific is expected to grow fastest through 2031. Key players include Sartorius, Danaher, Thermo Fisher Scientific, and Merck KGaA.Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "
Tracking Dan Loeb's Third Point Portfolio - Q2 2026 Update
Third Pointâs Q2 2026 13F: portfolio doubled to $4.68B as WBD becomes top holding; new buys include Keysight, Block; exits Meta/Nvidia. See more here.
3 Reasons DHR is Risky and 1 Stock to Buy Instead
Danaher currently trades at $204.89 per share and has shown little upside over the past six months, posting a middling return of 5%. The stock also fell short of the S&P 500’s 13.1% gain during that period.
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says
Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re
ILMN Stock Keeps Climbing. Should You Climb On?
A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others
500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro
Health Care's Next Act: Tailwinds Emerging Across R&D Cycle
Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Seen Deftly Navigating AI Integration
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment assumptions. […]
Why Moderna's Cancer Vaccine Matters To Investors
As legacy pharmaceutical models face structural challenges, targeting the underlying technology enablers of next-generation care offers a compelling approach for healthcare investors.
Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development at Global Scale
Genedata, the leading provider of enterprise software for biopharmaceutical R&D, today announced an expanded collaboration with Abcam, a global provider of validated antibodies and assay solutions. By deploying Genedata Biologics® across Abcam's global R&D organization, the two Danaher companies are working together to strengthen antibody development capabilities, unlock the value of scientific data, and accelerate AI-enabled innovation.
Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium
Danaher stock has delivered a decline of 26.6% over the past 5 years, yet current checks suggest the shares now trade near an intrinsic value estimate while still screening expensive on traditional multiples. The result is a company with mixed long term performance and a low overall value score, but without a clear discount on most valuation yardsticks. Over 5 years, Danaher shares are down 26.6%, which may lead some investors to question whether the recent pricing now already reflects that...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-21 | Blair Rainer | -7,755 | $219.3492 | $1,701,053 |
| 2026-08-21 | Blair Rainer | -39,193 | $218.7305 | $8,572,704 |
| 2026-08-21 | Blair Rainer | -11,307 | $217.7711 | $2,462,338 |
| 2026-08-04 | Gugino Matthew E | +153,563 | - | - |
| 2026-08-04 | Milosevich Gregory M | +15,402 | - | - |
| 2026-08-04 | Sawyer Montgomery Julie A | +245,701 | - | - |
| 2026-08-04 | Riley Christopher Paul | +41,072 | - | - |
| 2026-08-04 | Bouda Christopher | +12,286 | - | - |
| 2026-08-04 | Gutierrez-Ramos Jose-Carlos | +13,477 | - | - |
| 2026-08-04 | Leiken Jonathan | +92,138 | - | - |
| 2026-08-04 | RALES MITCHELL P | +1,000,000 | - | - |
| 2026-08-04 | RALES MITCHELL P | +500,000 | - | - |
| 2026-08-04 | RALES STEVEN M | +1,000,000 | - | - |
| 2026-08-04 | RALES STEVEN M | +500,000 | - | - |
| 2026-07-31 | Sanders A Shane | +211 | $194.98 | $41,141 |
| 2026-07-31 | Stevens Raymond C | +182 | $194.98 | $35,486 |
| 2026-07-31 | List Teri | +16 | $194.98 | $3,120 |
| 2026-07-31 | Dewan Feroz | +171 | $194.98 | $33,342 |
| 2026-07-31 | Zerhouni Elias A. | +237 | $194.98 | $46,210 |
| 2026-07-31 | FILLER LINDA | +18 | $194.98 | $3,510 |
| 2026-07-31 | SPOON ALAN G | +230 | $194.98 | $44,845 |
| 2026-07-15 | Bouda Christopher | -60 | $200.79 | $12,047 |
| 2026-07-15 | Zerhouni Elias A. | -3,298 | - | - |
| 2026-07-15 | Zerhouni Elias A. | -1,181 | $200.79 | $237,133 |
| 2026-07-15 | Zerhouni Elias A. | +3,298 | $71.88 | $237,060 |
| 2026-07-15 | FILLER LINDA | -3,298 | - | - |
| 2026-07-15 | FILLER LINDA | -1,181 | $200.79 | $237,133 |
| 2026-07-15 | FILLER LINDA | +3,298 | $71.88 | $237,060 |
| 2026-05-15 | Lamanna Charles W | +1,699 | - | - |
| 2026-05-15 | Lamanna Charles W | +680 | - | - |
| 2026-05-15 | Couchara Georgeann | -281 | $161.91 | $45,497 |
| 2026-05-15 | Sanders A Shane | +1,699 | - | - |
| 2026-05-15 | Sanders A Shane | +680 | - | - |
| 2026-05-15 | Stevens Raymond C | +1,699 | - | - |
| 2026-05-15 | Stevens Raymond C | +680 | - | - |
| 2026-05-15 | List Teri | +1,699 | - | - |
| 2026-05-15 | List Teri | +680 | - | - |
| 2026-05-15 | Dewan Feroz | +1,699 | - | - |
| 2026-05-15 | Dewan Feroz | +680 | - | - |
| 2026-05-15 | Zerhouni Elias A. | +1,699 | - | - |
| 2026-05-15 | Zerhouni Elias A. | +680 | - | - |
| 2026-05-15 | FILLER LINDA | +1,699 | - | - |
| 2026-05-15 | FILLER LINDA | +680 | - | - |
| 2026-05-15 | SPOON ALAN G | +1,699 | - | - |
| 2026-05-15 | SPOON ALAN G | +680 | - | - |
| 2026-05-01 | SPOON ALAN G | -3,298 | - | - |
| 2026-05-01 | SPOON ALAN G | -1,358 | $174.6737 | $237,207 |
| 2026-05-01 | SPOON ALAN G | +3,298 | $71.88 | $237,060 |
| 2026-04-24 | Sanders A Shane | +232 | $177.25 | $41,122 |
| 2026-04-24 | Stevens Raymond C | +199 | $177.25 | $35,273 |
| 2026-04-24 | List Teri | +17 | $177.25 | $3,013 |
| 2026-04-24 | Dewan Feroz | +188 | $177.25 | $33,323 |
| 2026-04-24 | Zerhouni Elias A. | +260 | $177.25 | $46,085 |
| 2026-04-24 | FILLER LINDA | +20 | $177.25 | $3,545 |
| 2026-04-24 | SPOON ALAN G | +252 | $177.25 | $44,667 |
| 2026-03-01 | Gugino Matthew E | +10,778 | - | - |
| 2026-03-01 | Gugino Matthew E | -231 | $210.64 | $48,658 |
| 2026-03-01 | Gugino Matthew E | +3,988 | - | - |
| 2026-03-01 | Milosevich Gregory M | +11,548 | - | - |
| 2026-03-01 | Milosevich Gregory M | -118 | $210.64 | $24,856 |
| 2026-03-01 | Milosevich Gregory M | +4,273 | - | - |
| 2026-03-01 | Sawyer Montgomery Julie A | +16,681 | - | - |
| 2026-03-01 | Sawyer Montgomery Julie A | -1,080 | $210.64 | $227,491 |
| 2026-03-01 | Sawyer Montgomery Julie A | +6,172 | - | - |
| 2026-03-01 | Riley Christopher Paul | +16,681 | - | - |
| 2026-03-01 | Riley Christopher Paul | -1,115 | $210.64 | $234,864 |
| 2026-03-01 | Riley Christopher Paul | +6,172 | - | - |
| 2026-03-01 | Couchara Georgeann | +12,831 | - | - |
| 2026-03-01 | Couchara Georgeann | -113 | $210.64 | $23,802 |
| 2026-03-01 | Couchara Georgeann | +4,748 | - | - |
| 2026-03-01 | Bouda Christopher | +3,369 | - | - |
| 2026-03-01 | Bouda Christopher | -170 | $210.64 | $35,809 |
| 2026-03-01 | Bouda Christopher | +1,247 | - | - |
| 2026-03-01 | McGrew Matthew | +16,039 | - | - |
| 2026-03-01 | McGrew Matthew | +5,935 | - | - |
| 2026-03-01 | Blair Rainer | +47,475 | - | - |
| 2026-03-01 | Blair Rainer | +17,566 | - | - |
| 2026-03-01 | Gutierrez-Ramos Jose-Carlos | +17,964 | - | - |
| 2026-03-01 | Gutierrez-Ramos Jose-Carlos | -284 | $210.64 | $59,822 |
| 2026-03-01 | Gutierrez-Ramos Jose-Carlos | +6,647 | - | - |
| 2026-03-01 | Leiken Jonathan | +6,416 | - | - |
| 2026-03-01 | Leiken Jonathan | +2,374 | - | - |
| 2026-03-01 | GRAY R BRADLEY | +7,699 | - | - |
| 2026-03-01 | GRAY R BRADLEY | +2,849 | - | - |
| 2026-02-27 | RALES MITCHELL P | -71,648 | - | - |
| 2026-02-24 | Milosevich Gregory M | -189 | $209.19 | $39,537 |
| 2026-02-24 | Sawyer Montgomery Julie A | -372 | $209.19 | $77,819 |
| 2026-02-24 | Riley Christopher Paul | -242 | $209.19 | $50,624 |
| 2026-02-24 | Couchara Georgeann | -101 | $209.19 | $21,128 |
| 2026-02-24 | Bouda Christopher | -235 | $209.19 | $49,160 |
| 2026-02-24 | Gutierrez-Ramos Jose-Carlos | -344 | $209.19 | $71,961 |
| 2026-02-19 | Milosevich Gregory M | -1,320 | - | - |
| 2026-02-19 | Milosevich Gregory M | -1,320 | $208.011 | $274,575 |
| 2026-02-19 | Milosevich Gregory M | +1,320 | $58.59 | $77,339 |
| 2026-02-04 | Milosevich Gregory M | +679 | - | - |
| 2026-02-04 | Sawyer Montgomery Julie A | +848 | - | - |
| 2026-02-04 | Riley Christopher Paul | +1,046 | - | - |
| 2026-02-04 | Couchara Georgeann | +1,413 | - | - |
| 2026-02-04 | McGrew Matthew | +2,684 | - | - |
| 2026-02-04 | Blair Rainer | +8,474 | - | - |
| 2026-02-04 | Gutierrez-Ramos Jose-Carlos | +1,695 | - | - |
| 2026-02-04 | Ellis Brian W | +1,695 | - | - |
| 2026-02-02 | Milosevich Gregory M | +629 | $228.92 | $143,991 |
| 2026-02-02 | Sawyer Montgomery Julie A | +510 | $218.89 | $111,634 |
| 2026-02-02 | Riley Christopher Paul | +547 | $218.89 | $119,733 |
| 2026-02-02 | Riley Christopher Paul | -640 | $223.42 | $142,989 |
| 2026-02-02 | Couchara Georgeann | +489 | $218.89 | $107,037 |
| 2026-02-02 | Bouda Christopher | +189 | $218.89 | $41,370 |
| 2026-02-02 | McGrew Matthew | +791 | $228.92 | $181,076 |
| 2026-02-02 | McGrew Matthew | -1,856 | $223.42 | $414,668 |
| 2026-02-02 | Blair Rainer | +1,835 | $228.92 | $420,068 |
| 2026-02-02 | Blair Rainer | -7,750 | $223.42 | $1,731,505 |
| 2026-02-02 | Gutierrez-Ramos Jose-Carlos | +275 | $218.89 | $60,195 |
| 2026-02-02 | Gutierrez-Ramos Jose-Carlos | -852 | $223.42 | $190,354 |
| 2026-02-02 | Ellis Brian W | +251 | $218.89 | $54,941 |
| 2026-02-02 | Ellis Brian W | -1,254 | $223.42 | $280,169 |
| 2026-02-02 | Leiken Jonathan | +41 | $218.89 | $8,974 |
| 2026-02-02 | GRAY R BRADLEY | +212 | $218.89 | $46,405 |
| 2026-02-02 | RALES MITCHELL P | +79 | $218.89 | $17,292 |
| 2026-01-30 | Sanders A Shane | +184 | $218.89 | $40,276 |
| 2026-01-30 | Stevens Raymond C | +159 | $218.89 | $34,804 |
| 2026-01-30 | List Teri | +11 | $218.89 | $2,408 |
| 2026-01-30 | Dewan Feroz | +151 | $218.89 | $33,052 |
| 2026-01-30 | Zerhouni Elias A. | +201 | $218.89 | $43,997 |
| 2026-01-30 | FILLER LINDA | +13 | $218.89 | $2,846 |
| 2026-01-30 | SPOON ALAN G | +193 | $218.89 | $42,246 |
| 2025-12-30 | RALES MITCHELL P | +1,544 | $230.67 | $356,154 |
| 2025-11-25 | RALES MITCHELL P | -4,726 | $231.19 | $1,092,604 |
| 2025-11-25 | RALES MITCHELL P | -35,899 | $230.27 | $8,266,463 |
| 2025-11-25 | RALES MITCHELL P | -22,029 | - | - |
| 2025-11-18 | List Teri | -3,298 | - | - |
| 2025-11-18 | List Teri | -3,298 | $226.5 | $746,997 |
| 2025-11-18 | List Teri | +3,298 | $71.88 | $237,060 |
| 2025-11-15 | Milosevich Gregory M | -35 | $221.21 | $7,742 |
| 2025-11-15 | Sawyer Montgomery Julie A | -265 | $221.21 | $58,621 |
| 2025-11-15 | Leiken Jonathan | +26,767 | - | - |
| 2025-11-15 | Leiken Jonathan | +10,172 | - | - |
| 2025-11-15 | GRAY R BRADLEY | -1,402 | $221.21 | $310,136 |
| 2025-11-12 | RALES MITCHELL P | -23,359 | $220.15 | $5,142,484 |
| 2025-11-12 | RALES MITCHELL P | -133,233 | $219.43 | $29,235,317 |
| 2025-11-12 | RALES MITCHELL P | -254,553 | $218.27 | $55,561,283 |
| 2025-11-12 | RALES MITCHELL P | -25,855 | $217.64 | $5,627,082 |
| 2025-11-12 | Ellis Brian W | -14,667 | - | - |
| 2025-11-12 | Ellis Brian W | -7,109 | - | - |
| 2025-11-12 | Ellis Brian W | -14,667 | $219.2321 | $3,215,477 |
| 2025-11-12 | Ellis Brian W | +14,667 | $58.59 | $859,340 |
| 2025-11-12 | Ellis Brian W | -7,109 | $219.2131 | $1,558,386 |
| 2025-11-12 | Ellis Brian W | +7,109 | $58.59 | $416,516 |
| 2025-11-11 | McGrew Matthew | -16,172 | - | - |
| 2025-11-11 | McGrew Matthew | -16,172 | $214.6198 | $3,470,831 |
| 2025-11-11 | McGrew Matthew | +16,172 | $62.85 | $1,016,410 |
| 2025-11-10 | Couchara Georgeann | -4,176 | - | - |
| 2025-11-10 | Couchara Georgeann | -998 | $210.3118 | $209,891 |
| 2025-11-10 | Couchara Georgeann | -4,176 | $210.4436 | $878,812 |
| 2025-11-10 | Couchara Georgeann | +4,176 | $88.24 | $368,490 |
| 2025-10-31 | RALES MITCHELL P | -68,128 | $217.17 | $14,795,358 |
| 2025-10-31 | RALES MITCHELL P | -223,449 | $216.26 | $48,323,081 |
| 2025-10-31 | RALES MITCHELL P | -308,423 | $215.67 | $66,517,588 |
| 2025-10-31 | Sanders A Shane | +186 | $215.38 | $40,061 |
| 2025-10-31 | Stevens Raymond C | +161 | $215.38 | $34,676 |
| 2025-10-31 | List Teri | +11 | $215.38 | $2,369 |
| 2025-10-31 | Dewan Feroz | +153 | $215.38 | $32,953 |
| 2025-10-31 | Zerhouni Elias A. | +203 | $215.38 | $43,722 |
| 2025-10-31 | FILLER LINDA | +13 | $215.38 | $2,800 |
| 2025-10-31 | SPOON ALAN G | +196 | $215.38 | $42,214 |